Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Acta Cardiol ; 77(3): 264-270, 2022 May.
Article in English | MEDLINE | ID: mdl-34006205

ABSTRACT

BACKGROUND: The pharmacological therapy of ventricular arrhythmias in patients with unsuccessful or not feasible catheter ablation and contraindication or inefficacy to amiodarone and beta-blockers, is controversial. The present study investigated the effectiveness and tolerability of mexiletine in patients with recurrent ventricular arrhythmias and ischaemic heart disease, when the conventional antiarrhythmic therapy failed. METHODS: We enrolled all consecutive patients with unsuccessful/not feasible catheter ablation and ineffective/contraindicated amiodarone or beta-blockers, which started the mexiletine treatment for refractory ventricular tachycardia (VT) or ventricular fibrillation (VF) between January 2010 and January 2020. The primary endpoint was the total number of VT/VF episodes after the beginning of mexiletine therapy. The 2 secondary endpoints were the overall number of therapies released by implantable cardioverter-defibrillators (ICDs) and the discontinuation of the pharmacological therapy. The events occurring during the mexiletine treatment period were compared with those observed in a matched duration interval before the initiation of therapy. RESULTS: Thirty-four consecutive patients (27 males, 79.4%; mean age 74.0 ± 9.5 years) with ischaemic heart disease were finally analysed. The median of mexiletine treatment was 26.5 months (interquartile range: 18.75-38.25 months). After the mexiletine start, VT/VF episodes and ICD interventions significantly decreased (respectively: 74 vs 33 episodes, p = 0.002; 116 vs 52 interventions, p = 0.02) in comparison with a matched period without mexiletine. Six patients (13.9%) discontinued the treatment because of severe side effects. CONCLUSIONS: The treatment period following the mexiletine start was associated with a significant reduction of ventricular arrhythmias. The rate of side effects requiring dosage reduction or interruption was not neglectable.


Subject(s)
Amiodarone , Coronary Artery Disease , Defibrillators, Implantable , Myocardial Ischemia , Tachycardia, Ventricular , Aged , Aged, 80 and over , Amiodarone/adverse effects , Anti-Arrhythmia Agents/therapeutic use , Cohort Studies , Coronary Artery Disease/complications , Defibrillators, Implantable/adverse effects , Female , Humans , Male , Mexiletine/therapeutic use , Middle Aged , Myocardial Ischemia/etiology , Tachycardia, Ventricular/etiology , Tachycardia, Ventricular/therapy , Ventricular Fibrillation/etiology , Ventricular Fibrillation/therapy
2.
J Arrhythm ; 37(2): 467-469, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33850596

ABSTRACT

We have described some unusual findings of radiofrequency interference with ICD functioning during AV nodal ablation, guiding the reader to the possible explanation of the phenomena.

4.
G Ital Cardiol (Rome) ; 21(6): 408-416, 2020 Jun.
Article in Italian | MEDLINE | ID: mdl-32425183

ABSTRACT

The COVID-19 post-lockdown period and the subsequent progressive withdrawal of the quarantine measures are currently allowing the gradual resumption of the ordinary clinical activities, which have been suppressed during the COVID-19 pandemic. In this phase, it is crucial to minimize the risk of infection to limit COVID-19-related morbidity and mortality and the number of new cases. Indeed, COVID-19 manifestations may be equivocal, including asymptomatic or mildly symptomatic patients. In order to ensure the safety of patients and healthcare providers, therefore, it is mandatory to stratify the risk of post-COVID-19 pandemic infection during the clinical and instrumental evaluation of cardiac patients, who are at low risk for COVID-19. Here we discuss the most common diagnostic procedures and therapeutic activities, the type of personal protective equipment according to the different tests, the timetable of the different diagnostic examinations, the tele-health services or alternative strategies, and the structural and management requirements, that should be applied to protect patients and healthcare providers in the post-COVID-19 era.


Subject(s)
Communicable Disease Control , Coronavirus Infections/prevention & control , Disease Transmission, Infectious/prevention & control , Heart Diseases , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , COVID-19 , Coronavirus Infections/transmission , Heart Diseases/diagnosis , Heart Diseases/therapy , Humans , Personal Protective Equipment , Pneumonia, Viral/transmission , Risk Assessment
6.
Am J Cardiol ; 93(5): 661-3, 2004 Mar 01.
Article in English | MEDLINE | ID: mdl-14996606

ABSTRACT

Primary school students (817 apparently healthy 10-year olds) were screened by transthoracic 2-dimensional echocardiography to assess for the prevalence of bicuspid aortic valve. Bicuspid aortic valve was found in 0.5% of cases, with a higher prevalence in males than females (0.75% vs 0.24%), and was significantly associated with aortic root enlargement compared with children who had tricuspid aortic valves.


Subject(s)
Aortic Valve/abnormalities , Aortic Valve/diagnostic imaging , Child , Female , Humans , Italy/epidemiology , Male , Prevalence , Prospective Studies , Rural Population/statistics & numerical data , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...